169 related articles for article (PubMed ID: 36951526)
21. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
22. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
[TBL] [Abstract][Full Text] [Related]
23. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
[TBL] [Abstract][Full Text] [Related]
24. Extremity Rhabdomyosarcoma-An Integrated Clinicopathologic and Genomic Study to Improve Risk Stratification.
de Traux de Wardin H; Xu B; Dermawan JK; Smith MH; Wolden SL; Antonescu CR; Wexler LH
JCO Precis Oncol; 2023 Jun; 7(1):e2200705. PubMed ID: 37315267
[TBL] [Abstract][Full Text] [Related]
25. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Rudzinski ER; Anderson JR; Hawkins DS; Skapek SX; Parham DM; Teot LA
Arch Pathol Lab Med; 2015 Oct; 139(10):1281-7. PubMed ID: 25989287
[TBL] [Abstract][Full Text] [Related]
26. The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.
Shenoy A; Alvarez E; Chi YY; Li M; Shern JF; Khan J; Hiniker SM; Granberg CF; Hawkins DS; Parham DM; Teot LA; Rudzinski ER
Eur J Cancer; 2021 Jan; 143():127-133. PubMed ID: 33302115
[TBL] [Abstract][Full Text] [Related]
27. Metabolic response as assessed by
Harrison DJ; Chi YY; Tian J; Hingorani P; Mascarenhas L; McCowage GB; Weigel BJ; Venkatramani R; Wolden SL; Yock TI; Rodeberg DA; Hayes-Jordan AA; Teot LA; Spunt SL; Meyer WH; Hawkins DS; Shulkin BL; Parisi MT
Cancer Med; 2021 Feb; 10(3):857-866. PubMed ID: 33340280
[TBL] [Abstract][Full Text] [Related]
28. Molecular biology of rhabdomyosarcoma.
Gallego Melcón S; Sánchez de Toledo Codina J
Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
[TBL] [Abstract][Full Text] [Related]
30. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Lautz TB; Xue W; Luo LY; Fair D; Qumseya A; Gao Z; Dasgupta R; Rodeberg D; Venkatramani R
Pediatr Blood Cancer; 2023 Jul; 70(7):e30357. PubMed ID: 37070563
[TBL] [Abstract][Full Text] [Related]
31. Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies.
Rogers T; Zanetti I; Coppadoro B; Martelli H; Jenney M; Minard-Colin V; Terwisscha van Scheltinga SEJ; Skerritt C; Fajardo RD; Guérin F; Kelsey A; Merks JHM; Mandeville H; Guillén G; Glosli H; De Corti F; Bisogno G
Pediatr Blood Cancer; 2022 Sep; 69(9):e29739. PubMed ID: 35460336
[TBL] [Abstract][Full Text] [Related]
32. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
[TBL] [Abstract][Full Text] [Related]
33. Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Stoner JA; Garcia-Henriquez N; Randall RL; Spunt SL; Arndt CA; Kao S; Paidas CN; Million L; Hawkins DS
Cancer; 2011 Jun; 117(11):2541-50. PubMed ID: 24048802
[TBL] [Abstract][Full Text] [Related]
34. Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group.
Raney RB; Anderson JR; Brown KL; Huh WW; Maurer HM; Meyer WH; Parham DM; Rodeberg DA; Wolden SL; Donaldson SS;
Pediatr Blood Cancer; 2010 Oct; 55(4):612-6. PubMed ID: 20806360
[TBL] [Abstract][Full Text] [Related]
35. Histology and fusion status in rhabdomyosarcoma.
Rudzinski ER
Am Soc Clin Oncol Educ Book; 2013; ():425-8. PubMed ID: 23714565
[TBL] [Abstract][Full Text] [Related]
36. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Pediatr Blood Cancer; 2019 Nov; 66(11):e27952. PubMed ID: 31397065
[TBL] [Abstract][Full Text] [Related]
37. Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma.
Kubota Y; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Sci Rep; 2022 Nov; 12(1):19381. PubMed ID: 36371419
[TBL] [Abstract][Full Text] [Related]
38. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
39. Changes in FXR1 expression after Chemotherapy for Rhabdomyosarcoma.
Xu MC; Ghani MO; Apple A; Chen H; Whiteside M; Borinstein SC; Correa H; Lovvorn HN
J Pediatr Surg; 2021 Jun; 56(6):1148-1156. PubMed ID: 33736876
[TBL] [Abstract][Full Text] [Related]
40. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
